Condition: Oligometastatic Disease · Metastases · Ablation Techniques · Sponsor: Gitte Fredberg Persson MD PhD
This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy. Patients with any category of OMD from any non-hematological cancer are eligible for inclusion. Local ablative therapy (LAT) includes surgical metastasectomy, radiotherapy, thermal ablation, and electroporations. The primary objective is to assess the time to failure of LAT strategy in patients with OMD from any primary cancer treated with all LAT modalities.
This description comes directly from the study's public registry record.
Michael RT Laursen, MD · +45 3868 9202 · michael.ruben.teindl.laursen@regionh.dk
Gitte F Persson · +453868 9299 · Gitte.Persson@regionh.dk
Always discuss trial participation with your own doctor first.
| Copenhagen University Hospital Rigshospitalet | Copenhagen, Capital Region of Denmark, Denmark | Not Yet Recruiting |
| Copenhagen University Hospital Herlev and Gentofte | Herlev, Capital Region of Denmark, Denmark | Recruiting |
| Hillerød Hospital | Hillerød, Capital Region of Denmark, Denmark | Not Yet Recruiting |
| Aarhus University Hospital | Aarhus, Central Jutland, Denmark | Not Yet Recruiting |
| Gødstrup Hospital | Herning, Central Jutland, Denmark | Not Yet Recruiting |
| Danish Center for Particle Therapy | Aarhus, Central Region Denmark, Denmark | Not Yet Recruiting |
| Aalborg University Hospital | Aalborg, Northern Region of Denmark, Denmark | Not Yet Recruiting |
| Zealand University Hospital, Roskilde and Næstved | Roskilde, Region Sjælland, Denmark | Not Yet Recruiting |
| Odense University Hospital | Odense, Southern Denmark Region, Denmark | Not Yet Recruiting |
| Sønderborg Hospital | Sønderborg, Southern Denmark Region, Denmark | Not Yet Recruiting |
| Vejle Hospital | Vejle, Southern Denmark Region, Denmark | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06356779